Business Wire

MA-ONAPSIS

Share
Onapsis Announces New Offering to Jumpstart Security for SAP Customers

Onapsis , the leader in business-critical application cybersecurity and compliance, today announced the release of Onapsis Assess Baseline. In a world where business-critical applications are under attack every day, this new offering accelerates organizations’ abilities to kickstart their SAP vulnerability management programs by better aligning with the SAP Security Baseline.

The exponential growth of targeted ransomware and the increased threat of cyber warfare due to global conflict means that organizations must re-evaluate how they secure their most critical systems. Amid this evolving, more aggressive threat landscape , companies struggle to keep up with patching the growing number of vulnerabilities exploited by threat actors to gain access to their business-critical applications. Onapsis Assess Baseline empowers companies of any size to accelerate time-to-value by simplifying deployment with a new SaaS-based, zero-footprint model and focusing on a core, targeted set of critical vulnerabilities as first steps on their journey to ensure cybersecurity, compliance, and availability of their SAP applications. When organizations are ready to take on more, Onapsis Assess Baseline offers easy expansion to additional scope for vulnerability management as well as capabilities for continuous threat monitoring and application security testing.

Key Organizational Benefits with Onapsis Assess Baseline:

  • Reduce Implementation Overhead with an Accelerated Deployment: Whether in their own cloud, on-premises, or through Onapsis’ SaaS platform, Assess Baseline offers quick deployment and implementation with zero footprint scanning.
  • Accelerate Time-to-Value for SAP Vulnerability Management: Onapsis SaaS users can scan with Assess Baseline against the SAP-recommended security baseline requirements for an organization’s SAP systems within hours. The scans deliver powerful context around critical vulnerabilities, instructions on how to mitigate, and confidence that patches were applied, saving valuable resource time.
  • Technology that Scales and Grows When You’re Ready: Deploy where you want. Scan across the entire SAP landscape. Start small and target the most critical systems first, get them aligned to a baseline, and then expand the security scope across the organization on your terms.

“Securing business-critical applications has always been challenging, but there’s a larger bullseye on the backs of organizations today - more than ever before - as sophisticated threat actors increasingly target Enterprise Resource Planning (ERP) systems,” said Mariano Nunez, CEO of Onapsis. “We have successfully helped the world’s largest and most sophisticated organizations integrate their business applications into their cybersecurity and compliance programs. Now, Assess Baseline makes it easy for customers who are getting started with their SAP application security programs to quickly and effectively jumpstart protecting the applications that power their businesses.”

The Onapsis Platform secures the critical SAP applications that keep the global economy running. The platform is purpose-built to deliver impactful vulnerability management, advanced threat detection, custom code inspection, and automated compliance that enables global organizations to accelerate their business and digital transformation initiatives. The Onapsis Platform is deeply informed by the latest threat intelligence and security guidance from the Onapsis Research Labs. This market-leading team has discovered more than 800 zero-day vulnerabilities and is responsible for multiple critical global CERT alerts.

“Today’s threat landscape requires a holistic approach to securing business-critical SAP applications such as ERP software,” said Steve Biskie, national ERP risk and automation services leader with RSM US LLP. “It is exciting to see Onapsis continuing to innovate its solutions to assist companies on their security maturity journey. The new Baseline license can help pave the way for more organizations to have an entry point into vulnerability management for SAP applications that could help keep their critical data and applications safe and compliant.”

Attending the SAP Sapphire conference? Visit the Onapsis booth to learn more: #PA219

To schedule a time to speak with an Onapsis expert while at Sapphire, please visit: https://onapsis.com/sapphire-22

About Onapsis

Onapsis protects the business-critical applications that run the global economy, from the core to the cloud. The company’s cybersecurity and compliance solution offering, The Onapsis Platform, uniquely delivers vulnerability management, threat detection and response, change assurance, and continuous compliance for business-critical applications from leading vendors such as SAP, Oracle, Salesforce, and other SaaS platforms.

Onapsis is headquartered in Boston, MA, with offices in Heidelberg, Germany and Buenos Aires, Argentina, and proudly serves more than 300 of the world’s leading brands, including 20% of the Fortune 100, 6 of the top 10 automotive companies, 5 of the top 10 chemical companies, 4 of the top 10 technology companies, and 3 of the top 10 oil and gas companies.

The Onapsis Platform is powered by the Onapsis Research Labs, the team responsible for the discovery and mitigation of more than 800 zero-day vulnerabilities in business-critical applications. The reach of our threat research and platform is broadened through leading consulting and audit firms such as Accenture, Deloitte, IBM, PwC, and KPMG — making Onapsis solutions the standard in helping organizations protect their cloud, hybrid, and on-premises business-critical information and processes. For more information, connect with us on Twitter or LinkedIn , or visit us at https://onapsis.com/ .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye